Clinton Musil Net Worth

Clinton Musil biography

Clinton Musil serves as Chief Business Officer of the Company. He served as Vice President, Corporate Development at ARMO Biosciences, an immuno-oncology company that was acquired by Eli Lilly and Company. From July 2017 to September 2017, Mr. Musil served as a Managing Director at Hercules Capital, an investment firm. From September 2014 to March 2017, Mr. Musil served as a Vice President in the Healthcare Investment Banking Group at Deutsche Bank AG, an investment bank. From July 2013 to July 2014, Mr. Musil served as a Vice President in the Healthcare Investment Banking Group at Wells Fargo & Company, an investment bank. Earlier in his career, Mr. Musil was an investor at Essex Woodlands, a healthcare-focused investment fund. Mr. Musil holds a B.S. in Molecular and Cellular Biology from the University of Arizona and an M.B.A. from Harvard Business School.

What is the salary of Clinton Musil?

As the Chief Business Officer of Personalis Inc, the total compensation of Clinton Musil at Personalis Inc is $1,066,750. There are 1 executives at Personalis Inc getting paid more, with Aaron Tachibana having the highest compensation of $3,003,510.

How old is Clinton Musil?

Clinton Musil is 38, he's been the Chief Business Officer of Personalis Inc since 2018. There are 16 older and no younger executives at Personalis Inc. The oldest executive at Personalis Inc is A. Blaine Bowman, 73, who is the Independent Director.

What's Clinton Musil's mailing address?

Clinton's mailing address filed with the SEC is C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Personalis Inc

Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci és Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.

What does Personalis Inc do?

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.

Personalis Inc executives and stock owners

Personalis Inc executives and other stock owners filed with the SEC include:

• Aaron Tachibana,
  Chief Financial Officer
• Clinton Musil,
  Chief Business Officer
• John Stephen West,
  Co-Founder, CEO, Pres & Director
• Paul Ricci,
  Independent Director
• John West,
  President, Chief Executive Officer, Director
• Dr. Richard Chen M.D., M.S., MS,
  Sr. VP of R&D and Chief Medical Officer
• Richard Chen,
  Chief Science Officer
• Aaron L. Tachibana,
  Sr. VP & CFO
• Dr. Richard Chen M.S., M.D., MS,
  Chief Scientific Officer
• A. Blaine Bowman,
  Independent Director
• Alan Colowick,
  Independent Director
• Karin Eastham,
  Independent Director
• Jonathan MacQuitty,
  Independent Chairman of the Board
• Kenneth Ludlum,
  Independent Director
• Patrick Balthrop,
  Independent Director
• Stephen Moore,
  General Counsel
• Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Michael J. Fitzpatrick,
  VP of Worldwide Sales
• Stephen M. Moore J.D.,
  VP, Gen. Counsel & Corp. Sec.
• Carol J. Tillis,
  VP of Fin. & Admin.
• Dr. Michael Snyder Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Atul Butte,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Kenneth J Widder,
  
• Olivia Kyusuk Bloom,
  
• Ken Ludlum,
  Director
• Mdv Partners, L.L.C.Mdv Ix ...,
  
• Venture Partners Viii Lp Li...,
  
• Venture Partners Select Iv,...,
  
• Llp Abingworth,
  
• Christopher M Hall,
  PRESIDENT AND CEO
• Venture Partners Select Iv,...,
  
• Ai, Inc. Tempus,
  10% owner
• Lonnie Shoff,